We are live on ! Find out more
ARTV

Artiva Biotherapeutics
ARTV

53 hedge funds and large institutions have $62.8M invested in Artiva Biotherapeutics in 2025 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 23 increasing their positions, 12 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

92% more repeat investments, than reductions

Existing positions increased: 23 | Existing positions reduced: 12

1.24% less ownership

Funds ownership: 87.12% → 85.88% (-1.2%)

7% less funds holding

Funds holding: 57 → 53 (-4)

50% less funds holding in top 10

Funds holding in top 10: 2 → 1 (-1)

57% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 7

71% less capital invested

Capital invested by funds: $213M → $62.8M (-$150M)

Holders
53
Holders Change
-4
Holders Change %
-7.02%
% of All Funds
0.71%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.01%
New
3
Increased
23
Reduced
12
Closed
7
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$1.08M
2
Geode Capital Management
Geode Capital Management
Massachusetts
+$511K
3
Citadel Advisors
Citadel Advisors
Florida
+$224K
4
N
Nuveen
North Carolina
+$158K
5
SEI Investments
SEI Investments
Pennsylvania
+$158K

Top Sellers

Rank Fund Capital Flow
1
VP
venBio Partners
California
-$1.73M
2
RI
RTW Investments
New York
-$1.5M
3
CAM
Cormorant Asset Management
Massachusetts
-$1.04M
4
EC
EcoR1 Capital
California
-$418K
5
Norges Bank
Norges Bank
Norway
-$302K
Name Holding Trade Value Shares
Change 		Change in
Stake
RCM
1
RA Capital Management
Massachusetts
$29.6M – – –
5VM
2
5AM Venture Management
California
$7.06M – – –
VA
3
VR Adviser
New York
$4.83M – – –
BlackRock
4
BlackRock
New York
$3.74M +$1.08M +199,158 +19%
VP
5
venBio Partners
California
$3.6M -$1.73M -320,996 -21%
Capital World Investors
6
Capital World Investors
California
$2.6M -$263K -48,764 -5%
Vanguard Group
7
Vanguard Group
Pennsylvania
$2.57M -$47K -8,711 -1%
Franklin Resources
8
Franklin Resources
California
$1.56M +$140 +26 +0%
Geode Capital Management
9
Geode Capital Management
Massachusetts
$1.23M +$511K +94,699 +30%
SB
10
Samsara BioCapital
California
$875K – – –
WP
11
Woodline Partners
California
$849K – – –
Wellington Management Group
12
Wellington Management Group
Massachusetts
$582K – – –
State Street
13
State Street
Massachusetts
$515K +$37.8K +7,000 +4%
LGM
14
Logos Global Management
California
$435K – – –
Citadel Advisors
15
Citadel Advisors
Florida
$435K +$224K +41,454 +40%
Northern Trust
16
Northern Trust
Illinois
$425K +$133K +24,564 +21%
Alyeska Investment Group
17
Alyeska Investment Group
Illinois
$300K – – –
Charles Schwab
18
Charles Schwab
California
$165K +$61.3K +11,355 +26%
N
19
Nuveen
North Carolina
$144K +$158K +29,281 +157%
ACP
20
Acuta Capital Partners
California
$136K +$7.86K +1,456 +3%
UBS Group
21
UBS Group
Switzerland
$129K +$41.6K +7,698 +22%
Goldman Sachs
22
Goldman Sachs
New York
$126K +$21K +3,882 +10%
Bank of New York Mellon
23
Bank of New York Mellon
New York
$99.9K – – –
SEI Investments
24
SEI Investments
Pennsylvania
$87.8K +$158K +29,281 New
Morgan Stanley
25
Morgan Stanley
New York
$83.5K -$51.1K -9,467 -25%
1
2 3

ARTV Hedge Fund Activity: Q1 2025 in Review

53 of the 7,459 institutional investors tracked by Wall St. Rank reported a position in Artiva Biotherapeutics (ARTV) for Q1 2025, worth a combined $62.8M — down 71% from $213M a quarter earlier.

Sellers outnumbered buyers: 7 funds closed out of ARTV and 3 opened new positions — a net loss of 4 holders — while 12 trimmed existing stakes and 23 added.

The largest buyer was BlackRock, adding an estimated $1.08M. The largest seller was venBio Partners, cutting an estimated $1.73M.

  • 53 institutional investors held Artiva Biotherapeutics (ARTV) as of Q1 2025, down from 57 in Q4 2024.
  • Funds reported $62.8M of Artiva Biotherapeutics stock for Q1 2025, down 71% quarter-over-quarter.
  • 3 funds opened new Artiva Biotherapeutics positions in Q1 2025 and 7 closed out, a net change of -4 holders.
  • The largest Artiva Biotherapeutics buyer in Q1 2025 was BlackRock, an estimated $1.08M added.
  • The largest Artiva Biotherapeutics seller in Q1 2025 was venBio Partners, an estimated $1.73M sold.

Based on aggregated 13F filings for Q1 2025.